{"component": "clause", "props": {"groups": [{"samples": [{"hash": "a20l9PR6XOM", "uri": "/contracts/a20l9PR6XOM#study-results", "label": "Option Agreement (Viropharma Inc)", "score": 19.0, "published": true}, {"hash": "6yCdpfrWcv0", "uri": "/contracts/6yCdpfrWcv0#study-results", "label": "Option Agreement (Viropharma Inc)", "score": 19.0, "published": true}], "snippet": "Each Party shall designate a contact person to be primarily responsible for communicating with such person\u2019s counterpart on all issues concerning the Initial Studies. Through such contact person, ViroPharma shall keep Schering reasonably informed on and involved in the progress of the Initial Studies, including by providing Schering with quarterly written status reports covering all of the Initial Studies. ViroPharma shall provide Schering with copies of all interim data and results generated from any of the Initial Studies, as well as all of the final data and results of each of the Initial Studies, including access to or copies of the database from each Interim Study in a format mutually agreeable to the Parties, promptly after they become available. All such data and results shall constitute Know-How, shall be treated as Confidential Information in accordance with Article 5, and shall only be used by Schering for the purpose of evaluating the Compound and the Product to determine whether or not to exercise the Option. The Parties acknowledge that the data and results from the Initial Studies are subject to disclosure to and use by Sanofi-Synthelabo as set forth in Section 3.3 of the SaSy Agreement.", "size": 2, "snippet_links": [{"key": "each-party", "type": "clause", "offset": [0, 10]}, {"key": "contact-person", "type": "clause", "offset": [29, 43]}, {"key": "responsible-for", "type": "clause", "offset": [60, 75]}, {"key": "all-issues", "type": "definition", "offset": [124, 134]}, {"key": "concerning-the", "type": "clause", "offset": [135, 149]}, {"key": "initial-studies", "type": "definition", "offset": [150, 165]}, {"key": "status-reports", "type": "clause", "offset": [358, 372]}, {"key": "copies-of-all", "type": "clause", "offset": [449, 462]}, {"key": "data-and-results", "type": "clause", "offset": [471, 487]}, {"key": "final-data", "type": "definition", "offset": [553, 563]}, {"key": "access-to", "type": "definition", "offset": [618, 627]}, {"key": "the-database", "type": "definition", "offset": [641, 653]}, {"key": "confidential-information", "type": "clause", "offset": [836, 860]}, {"key": "in-accordance-with", "type": "definition", "offset": [861, 879]}, {"key": "article-5", "type": "clause", "offset": [880, 889]}, {"key": "for-the-purpose-of", "type": "definition", "offset": [926, 944]}, {"key": "the-product", "type": "clause", "offset": [973, 984]}, {"key": "determine-whether", "type": "clause", "offset": [988, 1005]}, {"key": "to-exercise", "type": "clause", "offset": [1013, 1024]}, {"key": "the-option", "type": "clause", "offset": [1025, 1035]}, {"key": "the-parties-acknowledge", "type": "clause", "offset": [1037, 1060]}, {"key": "subject-to", "type": "definition", "offset": [1116, 1126]}, {"key": "by-sanofi", "type": "clause", "offset": [1149, 1158]}, {"key": "section-33", "type": "clause", "offset": [1186, 1197]}], "hash": "a1738376cdf0ef477cd48b0a201b66be", "id": 6}, {"samples": [{"hash": "jHT0QKey9ZU", "uri": "/contracts/jHT0QKey9ZU#study-results", "label": "Research Collaboration and License Agreement (Dicerna Pharmaceuticals Inc)", "score": 25.076659822, "published": true}, {"hash": "bwt6xpH3DpL", "uri": "/contracts/bwt6xpH3DpL#study-results", "label": "Research Collaboration and License Agreement (Dicerna Pharmaceuticals Inc)", "score": 25.0739219713, "published": true}, {"hash": "7tMLOume5NX", "uri": "/contracts/7tMLOume5NX#study-results", "label": "Research Collaboration and License Agreement (Dicerna Pharmaceuticals Inc)", "score": 25.0438056126, "published": true}], "snippet": "For purposes of clarity (a) the Parties hereby acknowledge and agree, in accordance with Section 1.77, that (1) all data and information obtained or produced in the conduct of the Feasibility Study and/or the Target Confirmation Study (the \u201cStudy Results\u201d) shall be jointly owned by the Parties and (2) subject to subsection (b) below, neither Party shall cause or allow any Study Results to be published without the prior written consent of the other Party; and (b) notwithstanding anything to the contrary in Section 10.4, Section 1.77 or subsection (D)(a) above, on and after the date on which [***] becomes a Waived Target pursuant to this Agreement, (1) DICERNA shall solely own the Study Results and have the sole right to use such Study Results for any and all purposes, inside or outside of this Agreement, without restriction, (2) DICERNA shall be deemed to have granted KHK the right to use such Study Results solely for internal research purposes and (3) as between the Parties, DICERNA shall have the sole right to publish such Study Results; provided, that, (i) any contribution of KHK to the Study Results shall be duly recognized and co-authorship shall be determined in accordance with customary industry standards and (ii) to the extent that any such Study Results to be published contain any Confidential Information of KHK, including without limitation KHK [***] DDS Technology or KHK Program Technology, DICERNA shall obtain the prior written consent of KHK to such publication.", "size": 3, "snippet_links": [{"key": "for-purposes-of", "type": "clause", "offset": [0, 15]}, {"key": "acknowledge-and-agree", "type": "clause", "offset": [47, 68]}, {"key": "in-accordance-with", "type": "definition", "offset": [70, 88]}, {"key": "data-and-information", "type": "definition", "offset": [116, 136]}, {"key": "conduct-of-the", "type": "clause", "offset": [165, 179]}, {"key": "feasibility-study", "type": "definition", "offset": [180, 197]}, {"key": "the-target", "type": "clause", "offset": [205, 215]}, {"key": "by-the-parties", "type": "clause", "offset": [280, 294]}, {"key": "subject-to", "type": "definition", "offset": [303, 313]}, {"key": "neither-party-shall", "type": "clause", "offset": [336, 355]}, {"key": "consent-of-the", "type": "clause", "offset": [431, 445]}, {"key": "other-party", "type": "definition", "offset": [446, 457]}, {"key": "notwithstanding-anything-to-the-contrary", "type": "clause", "offset": [467, 507]}, {"key": "waived-target", "type": "definition", "offset": [613, 626]}, {"key": "pursuant-to-this-agreement", "type": "clause", "offset": [627, 653]}, {"key": "the-study", "type": "definition", "offset": [684, 693]}, {"key": "right-to-use", "type": "clause", "offset": [720, 732]}, {"key": "all-purposes", "type": "definition", "offset": [764, 776]}, {"key": "the-right", "type": "clause", "offset": [884, 893]}, {"key": "internal-research-purposes", "type": "definition", "offset": [931, 957]}, {"key": "between-the-parties", "type": "clause", "offset": [969, 988]}, {"key": "right-to-publish", "type": "clause", "offset": [1018, 1034]}, {"key": "contribution-of", "type": "clause", "offset": [1079, 1094]}, {"key": "industry-standards", "type": "definition", "offset": [1212, 1230]}, {"key": "to-the-extent", "type": "clause", "offset": [1240, 1253]}, {"key": "confidential-information-of", "type": "clause", "offset": [1310, 1337]}, {"key": "including-without-limitation", "type": "clause", "offset": [1343, 1371]}, {"key": "program-technology", "type": "clause", "offset": [1404, 1422]}], "hash": "e785f10a1109852090a243f31173b4aa", "id": 3}, {"samples": [{"hash": "58ULkfBvWdA", "uri": "/contracts/58ULkfBvWdA#study-results", "label": "Requested Economic Planning Study Agreement", "score": 33.2464012556, "published": true}, {"hash": "3BLlB0r7td6", "uri": "/contracts/3BLlB0r7td6#study-results", "label": "Requested Economic Planning Study Agreement", "score": 31.6055777066, "published": true}, {"hash": "aC8C5cTsUb3", "uri": "/contracts/aC8C5cTsUb3#study-results", "label": "Requested Economic Planning Study Agreement", "score": 31.4933456358, "published": true}], "snippet": "7.1 Upon completion of the Requested Economic Planning Study, the NYISO will deliver the final written report of the completed Requested Economic Planning Study to Requestor, and, upon Requestor\u2019s request, the Parties will meet at a mutually agreeable time and place to review the results of the Requested Economic Planning Study.\n7.2 The NYISO will review the results of the Requested Economic Planning Studies to determine whether the results reveal Confidential Information that is not subject to disclosure under the NYISO\u2019s Code of Conduct. Confidential Information will be removed or the results aggregated or masked sufficiently to avoid the disclosure of Confidential Information. The NYISO will post the results of the Requested Economic Planning Study on its website if and when it is required to do so in accordance with Section 31.3.3.10 of Attachment Y to the OATT.", "size": 17, "snippet_links": [{"key": "upon-completion-of-the", "type": "clause", "offset": [4, 26]}, {"key": "planning-study", "type": "definition", "offset": [46, 60]}, {"key": "report-of-the", "type": "clause", "offset": [103, 116]}, {"key": "parties-will-meet", "type": "clause", "offset": [210, 227]}, {"key": "time-and-place", "type": "clause", "offset": [252, 266]}, {"key": "results-of-the", "type": "clause", "offset": [281, 295]}, {"key": "determine-whether", "type": "clause", "offset": [415, 432]}, {"key": "subject-to", "type": "definition", "offset": [489, 499]}, {"key": "code-of-conduct", "type": "definition", "offset": [529, 544]}, {"key": "disclosure-of-confidential-information", "type": "definition", "offset": [649, 687]}, {"key": "in-accordance-with", "type": "definition", "offset": [813, 831]}], "hash": "0d03429bfd1bc80a6488194cccb10cac", "id": 1}, {"samples": [{"hash": "ceHsyn5Ak8y", "uri": "/contracts/ceHsyn5Ak8y#study-results", "label": "Clinical Study Agreement", "score": 31.3390373502, "published": true}, {"hash": "jc0CHPv6MsF", "uri": "/contracts/jc0CHPv6MsF#study-results", "label": "Clinical Study Agreement", "score": 28.6399929162, "published": true}, {"hash": "hLldfMRgbj", "uri": "/contracts/hLldfMRgbj#study-results", "label": "Clinical Study Agreement", "score": 28.4675387586, "published": true}], "snippet": "After analysis of Study Data from all sites is complete, CRO or Pfizer will provide Principal Investigator with a summary of the overall results of the Study. CRO and Pfizer encourage Principal Investigator to communicate the results, as appropriate, to the Study Subjects. If within two years after Study completion Pfizer identifies results that could affect Study Subject safety, CRO or Pfizer, in consultation with SUKL/the IRB/IEC as appropriate, will cooperate with Principal Investigator or Institution to ensure that those results are appropriately communicated to the Study Subjects by Principal Investigator or Institution.", "size": 13, "snippet_links": [{"key": "study-data", "type": "clause", "offset": [18, 28]}, {"key": "will-provide", "type": "clause", "offset": [71, 83]}, {"key": "summary-of-the", "type": "clause", "offset": [114, 128]}, {"key": "the-study", "type": "definition", "offset": [148, 157]}, {"key": "study-subjects", "type": "definition", "offset": [258, 272]}, {"key": "two-years", "type": "clause", "offset": [284, 293]}, {"key": "study-completion", "type": "clause", "offset": [300, 316]}, {"key": "subject-safety", "type": "clause", "offset": [367, 381]}, {"key": "in-consultation-with", "type": "definition", "offset": [398, 418]}, {"key": "cooperate-with", "type": "clause", "offset": [457, 471]}, {"key": "to-ensure", "type": "clause", "offset": [510, 519]}, {"key": "by-principal-investigator-or-institution", "type": "clause", "offset": [592, 632]}], "hash": "700ccbdd62093a09d6b72c088a8b31e8", "id": 2}, {"samples": [{"hash": "iaIKOAiAi5V", "uri": "/contracts/iaIKOAiAi5V#study-results", "label": "Research and Development Agreement (Innexus Biotechnology Inc)", "score": 21.0, "published": true}, {"hash": "dIQQvT3QaD8", "uri": "/contracts/dIQQvT3QaD8#study-results", "label": "Research and Development Agreement (Innexus Biotechnology Inc)", "score": 21.0, "published": true}], "snippet": "InNexus will provide to CORIXA reports of the results for each of the experiments or studies InNexus conducts as outlined in Exhibit B, such reports to be provided to CORIXA in a timely manner following the completion of each experiment or study. Any and all reports communicated to CORIXA by InNexus within the scope of this Agreement, may be freely used by CORIXA but only for its own internal purposes. CORIXA will provide to InNexus reports of the results for each of the experiments or studies CORIXA conducts as outlined in Exhibit B, such reports to be provided to InNexus in a timely manner following the completion of each experiment or study. Any and all reports communicated to InNexus by CORIXA within the scope of this Agreement, may be freely used by InNexus for its own internal purposes.", "size": 2, "snippet_links": [{"key": "will-provide", "type": "clause", "offset": [8, 20]}, {"key": "reports-of", "type": "clause", "offset": [31, 41]}, {"key": "exhibit-b", "type": "definition", "offset": [125, 134]}, {"key": "reports-to", "type": "definition", "offset": [141, 151]}, {"key": "in-a-timely-manner", "type": "definition", "offset": [174, 192]}, {"key": "following-the", "type": "definition", "offset": [193, 206]}, {"key": "completion-of", "type": "clause", "offset": [207, 220]}, {"key": "scope-of-this-agreement", "type": "clause", "offset": [312, 335]}, {"key": "by-corixa", "type": "clause", "offset": [356, 365]}, {"key": "internal-purposes", "type": "definition", "offset": [387, 404]}], "hash": "5f67674ad7335e75148dbd5b7333ec05", "id": 4}, {"samples": [{"hash": "sSNwKZW9v2", "uri": "/contracts/sSNwKZW9v2#study-results", "label": "Investor Rights Agreement (Rio Tinto PLC)", "score": 33.8925393566, "published": true}, {"hash": "Rx4IRz7W2a", "uri": "/contracts/Rx4IRz7W2a#study-results", "label": "Subscription Agreement (Rio Tinto PLC)", "score": 31.8925393566, "published": true}], "snippet": "Following the Subscription Closing Date, the Corporation shall provide to the Investor a draft of any press release announcing the results of the Study, and shall consider, acting reasonably, any comments made by the Investor thereon; provided, however, that the Corporation shall not be required to provide such opportunity to comment in the event that, in the opinion of its outside legal counsel, the Corporation is required to make immediate disclosure of such results under Securities Laws. The foregoing right of the Investor shall terminate upon the earlier of: (a) the Investor\u2019s Ownership Percentage falling below 5.0%; and (b) the later of (i) the date that is 18 months following the Subscription Closing Date and (ii) 6 months following completion of the Study; provided, however, that the Corporation and the Investor may mutually agree to extend the time periods referred to in (b) above by such additional period of time as may be agreed in writing between the Corporation and the Investor.", "size": 2, "snippet_links": [{"key": "subscription-closing-date", "type": "definition", "offset": [14, 39]}, {"key": "investor-a", "type": "definition", "offset": [78, 88]}, {"key": "press-release", "type": "definition", "offset": [102, 115]}, {"key": "results-of-the", "type": "clause", "offset": [131, 145]}, {"key": "acting-reasonably", "type": "clause", "offset": [173, 190]}, {"key": "by-the-investor", "type": "clause", "offset": [210, 225]}, {"key": "to-provide", "type": "definition", "offset": [297, 307]}, {"key": "opportunity-to-comment", "type": "clause", "offset": [313, 335]}, {"key": "in-the-event", "type": "clause", "offset": [336, 348]}, {"key": "outside-legal-counsel", "type": "definition", "offset": [377, 398]}, {"key": "disclosure-of", "type": "clause", "offset": [446, 459]}, {"key": "securities-laws", "type": "clause", "offset": [479, 494]}, {"key": "the-foregoing", "type": "definition", "offset": [496, 509]}, {"key": "right-of-the", "type": "clause", "offset": [510, 522]}, {"key": "ownership-percentage", "type": "definition", "offset": [588, 608]}, {"key": "completion-of-the-study", "type": "clause", "offset": [749, 772]}, {"key": "the-corporation-and-the", "type": "clause", "offset": [798, 821]}, {"key": "to-extend", "type": "clause", "offset": [850, 859]}, {"key": "time-periods", "type": "definition", "offset": [864, 876]}, {"key": "period-of-time", "type": "clause", "offset": [921, 935]}, {"key": "in-writing", "type": "clause", "offset": [953, 963]}], "hash": "b729cbbd8ff399e17a557498db5ed728", "id": 5}, {"samples": [{"hash": "929776Hfvvy", "uri": "/contracts/929776Hfvvy#study-results", "label": "Clinical Study Agreement", "score": 34.5275938974, "published": true}], "snippet": "After analysis of Study Data from all sites is complete, Pfizer will provide Principal Investigator with a summary of the overall results of the Study. Pfizer encourages Principal Investigator to communicate the results, as appropriate, to the Study Subjects. If within two years after Study completion \u2587\u2587\u2587\u2587\u2587\u2587 identifies results that could affect Study Subject safety, Pfizer, in consultation with SUKL/the IRB/IEC as appropriate, will cooperate with Principal Investigator or Institution to ensure that those results are appropriately communicated to the Study Subjects by Principal Investigator or Institution.", "size": 2, "snippet_links": [{"key": "study-data", "type": "clause", "offset": [18, 28]}, {"key": "will-provide", "type": "clause", "offset": [64, 76]}, {"key": "summary-of-the", "type": "clause", "offset": [107, 121]}, {"key": "the-study", "type": "definition", "offset": [141, 150]}, {"key": "study-subjects", "type": "definition", "offset": [244, 258]}, {"key": "two-years", "type": "clause", "offset": [270, 279]}, {"key": "study-completion", "type": "clause", "offset": [286, 302]}, {"key": "subject-safety", "type": "clause", "offset": [353, 367]}, {"key": "in-consultation-with", "type": "definition", "offset": [377, 397]}, {"key": "cooperate-with", "type": "clause", "offset": [436, 450]}, {"key": "to-ensure", "type": "clause", "offset": [489, 498]}, {"key": "by-principal-investigator-or-institution", "type": "clause", "offset": [571, 611]}], "hash": "ab74659bd10c20ec2266e978c5cb008c", "id": 7}, {"samples": [{"hash": "kuwVoqZjP39", "uri": "/contracts/kuwVoqZjP39#study-results", "label": "Study Agreement", "score": 23.1744855597, "published": true}], "snippet": "8.1 Upon completion of the Additional Reliability Study, issuance of the final invoice and payment by Requestor of any amount due pursuant to Section 7.3 of this Agreement, the NYISO and Transmission Owner will jointly deliver the results of the completed Additional Reliability Study to Requestor, and the Parties will meet at a mutually agreeable time and place to review the results of the Additional Reliability Study. The NYISO and Transmission Owner will also provide the results of the Additional Reliability Study to Requestor in electronic format.\n8.2 The NYISO and Transmission Owner will review the results of the Additional Reliability Studies to determine whether the results reveal Confidential Information that may not be disclosed to the Requestor pursuant to the NYISO\u2019s Code of Conduct or is otherwise identified by Transmission Owner as their own Confidential Information. Prior to the delivery to the Requestor of the study results, NYISO and Transmission Owner will remove or sufficiently mask all Confidential Information to avoid the disclosure of any Confidential Information to the Requestor. The NYISO and Transmission Owner will treat the Study Request and the results of the Additional Reliability Study as Confidential Information in accordance with Attachment F to the OATT. The NYISO will not include the results of the Additional Reliability Study in the Reliability Needs Assessment or Comprehensive Reliability Plan. Notwithstanding the foregoing, the Requestor acknowledges and agrees that the NYISO and Transmission Owner shall be free to provide appropriate response to the New York State Department of Public Services (NYSDPS) with regard to any requests for information they may submit to the NYISO or Transmission Owner regarding the generator or the study, the scope of work after the Requestor has been provided written notice of the NYSDPS\u2019s request for information. In responding to such requests all Parties shall treat the study and the study results as confidential, commercial sensitive, proprietary information of the Requestor. The Requestor further acknowledges and agrees that the NYISO and Transmission Owner may disclose the results of this study, and that the NYISO may post the results of the Additional Reliability Study on its website, if and when Requestor seeks to obtain regulated cost recovery from an applicable state or federal regulatory authority based upon the results of the Additional Reliability Study or if the Requestor otherwise discloses the study request or the study results in the public domain.\n8.3 The Requestor acknowledges and agrees that the NYISO and the Transmission Owner shall be free to conduct an independent analysis as part of the NYISO\u2019s Reliability Planning Processes or Transmission Owner\u2019s local transmission planning efforts, if either Party determines, in its sole discretion and at its sole cost, that such analysis is appropriate.\n8.4 The Requestor acknowledges and agrees that, notwithstanding the provisions of this agreement indicating that it will not receive Confidential Information from the NYISO or Transmission Owner, in the event that Requestor does receive Confidential Information of the NYISO or the Transmission Owner as a result of its interactions with NYISO and Transmission Owner or otherwise arising out of the performance of this study or review of the study results, it shall not use such information for its advantage, it shall destroy such information, and it shall take all other necessary steps to prevent any further disclosure of that Confidential Information within its organization and to third parties.\n8.5 The Requestor further acknowledges and agrees that the NYISO and Transmission Owner may disclose the results of this study, and that the NYISO may post the results of the Additional Reliability Study on its website, if and when Requestor seeks to obtain regulated cost recovery from an applicable state or federal regulatory authority based upon the results of the Additional Reliability Study.\n8.6 Nothing in this Agreement shall be construed to limit the NYISO\u2019s authority to determine the need for, or Transmission Owner\u2019s authority to develop and propose, a regulated backstop or gap solution pursuant to NYISO OATT Attachment Y or any local transmission planning project.", "size": 2, "snippet_links": [{"key": "upon-completion-of-the", "type": "clause", "offset": [4, 26]}, {"key": "payment-by", "type": "clause", "offset": [91, 101]}, {"key": "section-73", "type": "clause", "offset": [142, 153]}, {"key": "owner-will", "type": "clause", "offset": [200, 210]}, {"key": "results-of-the", "type": "clause", "offset": [231, 245]}, {"key": "parties-will-meet", "type": "clause", "offset": [307, 324]}, {"key": "time-and-place", "type": "clause", "offset": [349, 363]}, {"key": "provide-the", "type": "clause", "offset": [466, 477]}, {"key": "electronic-format", "type": "definition", "offset": [538, 555]}, {"key": "determine-whether", "type": "clause", "offset": [659, 676]}, {"key": "pursuant-to-the", "type": "clause", "offset": [764, 779]}, {"key": "code-of-conduct", "type": "definition", "offset": [788, 803]}, {"key": "delivery-to-the", "type": "clause", "offset": [905, 920]}, {"key": "the-study", "type": "definition", "offset": [934, 943]}, {"key": "all-confidential-information", "type": "clause", "offset": [1015, 1043]}, {"key": "disclosure-of", "type": "clause", "offset": [1057, 1070]}, {"key": "any-confidential-information", "type": "clause", "offset": [1071, 1099]}, {"key": "in-accordance-with", "type": "definition", "offset": [1260, 1278]}, {"key": "attachment-f", "type": "definition", "offset": [1279, 1291]}, {"key": "needs-assessment", "type": "definition", "offset": [1399, 1415]}, {"key": "notwithstanding-the-foregoing", "type": "clause", "offset": [1451, 1480]}, {"key": "to-provide", "type": "definition", "offset": [1572, 1582]}, {"key": "department-of", "type": "clause", "offset": [1626, 1639]}, {"key": "public-services", "type": "definition", "offset": [1640, 1655]}, {"key": "with-regard-to", "type": "clause", "offset": [1665, 1679]}, {"key": "requests-for-information", "type": "clause", "offset": [1684, 1708]}, {"key": "submit-to", "type": "clause", "offset": [1718, 1727]}, {"key": "the-generator", "type": "clause", "offset": [1770, 1783]}, {"key": "the-scope-of-work", "type": "clause", "offset": [1798, 1815]}, {"key": "notice-of-the", "type": "clause", "offset": [1862, 1875]}, {"key": "request-for-information", "type": "definition", "offset": [1885, 1908]}, {"key": "responding-to", "type": "clause", "offset": [1913, 1926]}, {"key": "all-parties", "type": "definition", "offset": [1941, 1952]}, {"key": "proprietary-information", "type": "definition", "offset": [2036, 2059]}, {"key": "may-post", "type": "clause", "offset": [2221, 2229]}, {"key": "cost-recovery", "type": "definition", "offset": [2342, 2355]}, {"key": "applicable-state", "type": "definition", "offset": [2364, 2380]}, {"key": "regulatory-authority", "type": "definition", "offset": [2392, 2412]}, {"key": "in-the-public-domain", "type": "definition", "offset": [2551, 2571]}, {"key": "the-transmission", "type": "clause", "offset": [2634, 2650]}, {"key": "independent-analysis", "type": "clause", "offset": [2685, 2705]}, {"key": "planning-processes", "type": "clause", "offset": [2741, 2759]}, {"key": "local-transmission-planning", "type": "clause", "offset": [2784, 2811]}, {"key": "if-either-party", "type": "clause", "offset": [2821, 2836]}, {"key": "sole-discretion", "type": "clause", "offset": [2856, 2871]}, {"key": "provisions-of-this-agreement", "type": "clause", "offset": [2997, 3025]}, {"key": "information-from", "type": "clause", "offset": [3075, 3091]}, {"key": "in-the-event", "type": "clause", "offset": [3125, 3137]}, {"key": "confidential-information-of", "type": "clause", "offset": [3166, 3193]}, {"key": "arising-out-of", "type": "definition", "offset": [3309, 3323]}, {"key": "the-performance", "type": "clause", "offset": [3324, 3339]}, {"key": "review-of-the", "type": "clause", "offset": [3357, 3370]}, {"key": "such-information", "type": "definition", "offset": [3403, 3419]}, {"key": "necessary-steps", "type": "clause", "offset": [3502, 3517]}, {"key": "further-disclosure", "type": "clause", "offset": [3533, 3551]}, {"key": "organization-and", "type": "clause", "offset": [3596, 3612]}, {"key": "to-third-parties", "type": "clause", "offset": [3613, 3629]}, {"key": "nothing-in-this-agreement", "type": "clause", "offset": [4034, 4059]}, {"key": "authority-to", "type": "clause", "offset": [4100, 4112]}, {"key": "determine-the", "type": "clause", "offset": [4113, 4126]}, {"key": "to-develop", "type": "definition", "offset": [4171, 4181]}, {"key": "nyiso-oatt", "type": "definition", "offset": [4244, 4254]}, {"key": "planning-project", "type": "definition", "offset": [4294, 4310]}], "hash": "76033324567a5b20b0b2c5cccb8cdc61", "id": 8}, {"samples": [{"hash": "kAQ1c7oIWAn", "uri": "/contracts/kAQ1c7oIWAn#study-results", "label": "Clinical Study Agreement", "score": 30.8107254072, "published": true}], "snippet": "After analysis of Study Data from all sites is complete, CRO or Pfizer will provide Principal Investigator and Institution with a summary of the overall results of the Study. If within two years after Study completion Pfizer identifies results that could affect Study Subject safety, CRO or Pfizer, in consultation with SUKL/the relevant IEC as appropriate, will cooperate with Principal d. V\u00fdsledky Studie. Po dokon\u010den\u00ed anal\u00fdzy Studijn\u00edch \u00fadaj\u016f ze v\u0161ech pracovi\u0161\u0165, poskytne spole\u010dnost Pfizer nebo CRO Hlavn\u00edmu zkou\u0161ej\u00edc\u00edmu a Instituci shrnut\u00ed celkov\u00fdch v\u00fdsledk\u016f Studie; Pokud spole\u010dnost Pfizer do dvou let od dokon\u010den\u00ed Studie identifikuje v\u00fdsledky, kter\u00e9 by mohly ovlivnit bezpe\u010dnost subjekt\u016f Studie, bude CRO nebo spole\u010dnost Pfizer po porad\u011b se S\u00daKL/ p\u0159\u00edslu\u0161nou EK vhodn\u00fdm zp\u016fsobem spolupracovat Investigator or Institution to ensure that those results are appropriately communicated to the Study Subjects by Principal Investigator or Institution. s Hlavn\u00edm zkou\u0161ej\u00edc\u00edm nebo Instituc\u00ed na tom, aby zajistila, \u017ee v\u00fdsledky budou Hlavn\u00edm zkou\u0161ej\u00edc\u00edm nebo Instituc\u00ed odpov\u00eddaj\u00edc\u00edm zp\u016fsobem sd\u011bleny subjekt\u016fm Studie.", "size": 1, "snippet_links": [{"key": "study-data", "type": "clause", "offset": [18, 28]}, {"key": "will-provide", "type": "clause", "offset": [71, 83]}, {"key": "investigator-and-institution", "type": "clause", "offset": [94, 122]}, {"key": "summary-of-the", "type": "clause", "offset": [130, 144]}, {"key": "the-study", "type": "definition", "offset": [164, 173]}, {"key": "two-years", "type": "clause", "offset": [185, 194]}, {"key": "study-completion", "type": "clause", "offset": [201, 217]}, {"key": "subject-safety", "type": "clause", "offset": [268, 282]}, {"key": "in-consultation-with", "type": "definition", "offset": [299, 319]}, {"key": "the-relevant", "type": "clause", "offset": [325, 337]}, {"key": "cooperate-with", "type": "clause", "offset": [363, 377]}, {"key": "v\u00fdsledky-studie", "type": "clause", "offset": [391, 406]}, {"key": "dokon\u010den\u00ed-studie", "type": "clause", "offset": [610, 626]}, {"key": "to-ensure", "type": "clause", "offset": [826, 835]}, {"key": "study-subjects", "type": "definition", "offset": [893, 907]}, {"key": "by-principal-investigator-or-institution", "type": "clause", "offset": [908, 948]}], "hash": "8403dbc42ad7dfe6d14793d65f33f554", "id": 9}, {"samples": [{"hash": "cHbCkf8QZHZ", "uri": "/contracts/cHbCkf8QZHZ#study-results", "label": "License, Development and Commercialization Agreement (Social Capital Suvretta Holdings Corp. I)", "score": 33.2546201232, "published": true}], "snippet": "TALi shall keep \u2587\u2587\u2587\u2587\u2587 appropriately and routinely informed regarding progress with respect to activities assigned to TALi under the Study Plans, including all the study results and conclusions generated therefrom, and provide \u2587\u2587\u2587\u2587\u2587 access to all evidence generated from the performance of such activities. If TALi has a reason to expect that any of the timelines set forth in the Study Plans will be materially delayed, it will promptly notify the \u2587\u2587\u2587\u2587\u2587 thereof providing reasonable specificity regarding the timeline that has or will be missed and the cause thereof, in which case the Parties (through a Working Group) shall promptly meet and discuss how to address such matter and to agree any extension to the Initial Study Period.", "size": 1, "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [78, 93]}, {"key": "activities-assigned", "type": "clause", "offset": [94, 113]}, {"key": "study-plans", "type": "clause", "offset": [132, 143]}, {"key": "results-and-conclusions", "type": "clause", "offset": [169, 192]}, {"key": "access-to", "type": "definition", "offset": [232, 241]}, {"key": "the-performance", "type": "clause", "offset": [270, 285]}, {"key": "in-the-study", "type": "clause", "offset": [373, 385]}, {"key": "the-\u2587", "type": "clause", "offset": [444, 449]}, {"key": "the-parties", "type": "definition", "offset": [582, 593]}, {"key": "working-group", "type": "definition", "offset": [605, 618]}, {"key": "meet-and-discuss", "type": "definition", "offset": [635, 651]}, {"key": "study-period", "type": "definition", "offset": [721, 733]}], "hash": "c2c1318d099624715a982ec3acb3f7eb", "id": 10}], "next_curs": "ClYSUGoVc35sYXdpbnNpZGVyY29udHJhY3RzcjILEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2IhZzdHVkeS1yZXN1bHRzIzAwMDAwMDBhDKIBAmVuGAAgAA==", "clause": {"size": 72, "parents": [["study-data", "Study Data"], ["povinnosti", "Povinnosti"], ["return-of-confidential-information", "Return of Confidential Information"], ["other-covenants", "Other Covenants"], ["definitions", "Definitions"]], "children": [["publication-and-copyrights", "Publication and Copyrights"], ["", ""], ["compensation-by-itself", "Compensation by itself"], ["compensation-according-to-civil-law-code", "Compensation according to civil law code"], ["compensation-according-to-presidential-regulation-for-goods", "Compensation according to presidential regulation for goods"]], "title": "Study Results", "id": "study-results", "related": [["study", "Study", "Study"], ["clinical", "Clinical", "Clinical"], ["clinical-studies", "Clinical Studies", "Clinical Studies"], ["tests-and-preclinical-and-clinical-trials", "Tests and Preclinical and Clinical Trials", "Tests and Preclinical and Clinical Trials"], ["clinical-trials", "Clinical Trials", "Clinical Trials"]], "related_snippets": [], "updated": "2025-07-07T12:36:22+00:00", "also_ask": ["What key protections should be included to control ownership and use of study results?", "How can parties negotiate publication rights versus confidentiality obligations?", "What are the main risks if study results are not clearly defined or allocated?", "How do courts typically interpret ambiguous study results clauses in disputes?", "How does this clause compare to industry standards for data sharing and IP rights?"], "drafting_tip": "Define what constitutes 'Study Results' to avoid ambiguity; specify ownership and permitted uses to ensure enforceability and protect parties' interests.", "explanation": "The \"Study Results\" clause defines how the findings and data generated from a research study will be handled, reported, and shared between the parties involved. Typically, this clause outlines the process for reviewing, publishing, or disclosing study outcomes, and may specify timelines, confidentiality obligations, or rights to review results before public release. Its core practical function is to ensure that both parties have clear expectations regarding the management and dissemination of study results, thereby protecting proprietary information and supporting coordinated communication."}, "json": true, "cursor": ""}}